..
..
..
Corbevax[1] or BioE COVID-19, is a COVID-19 vaccine developed by Indian biopharmacutical firm Biological E. Limited (BioE), the Baylor College of Medicine in Houston, United States, and American company Dynavax Technologies (DVAX). It is a protein subunit vaccine.[2][3][4][5]
The vaccine consists of a version of the receptor binding domain (RBD) of the SARS‑CoV‑2spike protein, together with the adjuvantsaluminium hydroxide gel and CpG 1018.[3] The protein is produced by the yeastPichia pastoris; the process is similar to that of existing Hepatitis B vaccines.[3]
In April 2021, the U.S. International Development Finance Corporation (DFC) announced that it would fund the expansion of BioE’s manufacturing capabilities, so that it could produce at least 1 billion doses by end of 2022.[6]
In phase I clinical trial was carried to evaluate the safety and immunogenicity of the vaccine candidate in about 360 participants.[5] The phase II concluded in April 2021.[7][8]
In April 2021, the Drugs Controller General of India permitted the vaccine candidate to start phase III clinical trials. A total of 1,268 healthy participants between the age of 18 and 80 years to be selected from 15 sites across India for the trial and intended to be part of a larger global Phase III study.[9][8]
In July 2021, The Philippines is set to use the vaccine. Currently, an emergency use authorization (EUA) is being applied in the Philippines’ Food and Drug administration.[10]
On 28 December 2021, India approved the vaccine for emergency use.[11]
On 3 June 2021, India’s Ministry of Health and Family Welfare pre-ordered 300 million doses of Corbevax.[12]
The company has estimated the vaccine to be priced at ₹250 (around $3) per dose and may even be priced below ₹400 (around $5) for two doses in India.[13]
https://en.wikipedia.org/wiki/Corbevax
..
..
..
..
..
..
..
..
..
..
weehingthong 